Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Oncology

Journal Scan / Research · March 11, 2024

Lurbinectedin in Patients With SCLC With Chemotherapy-Free Interval ≥30 Days and No CNS Metastases

Lung Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Lung Cancer
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Lung Cancer 2024 Feb 01;188(xx)107448, S Peters, J Trigo, B Besse, V Moreno, A Navarro, M Eugenia Olmedo, L Paz-Ares, C Grohé, J Antonio Lopez-Vilariño, C Fernández, C Kahatt, V Alfaro, A Nieto, A Zeaiter, V Subbiah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading